Over 46 million people worldwide are estimated to live with dementia, of which approximately 75% are attributable to AD. 1 The prevalence of AD increases rapidly after 65 years of age. At any one time approximately 20-25% of people with AD experience psychotic symptoms, which become more common at later stages. Over the entire course of the disease, 50-60% of patients with AD experience at least one of these episodes. 2 In a study of 124 patients with dementia due to AD, 67% had psychotic symptoms occurring 2-6 times per week. For 32% of these patients, the symptoms lasted for 12 weeks and recurred in 50% within 12 months. The frequencies of psychotic episodes are greater in patients with Lewy bodies in brain neural cells. Hallucinations in AD tend to be visual rather than auditory, tactile or olfactory, which distinguishes AD and Parkinson's disease (PD), schizophrenia, psychotic depression or mania. Persecutory delusions occur earlier in AD than misidentification delusions; both types increase with dementia severity.
Q: How does the incidence of psychotic episodes affect disease progression in AD?
Substantial evidence indicates that the presence of psychotic symptoms has a detrimental effect on the course of AD. 2 Psychotic symptoms are associated with more aggressive disease and a more rapid rate of decline. For example, this was demonstrated in two large cohort studies (n=335 and n=1,821) of patients with incident AD in which presence of clinically significant psychotic symptoms was strongly associated with progression from mild cognitive impairment to dementia (hazard ratios 1.47 and 2.68) and in one of these studies was associated with earlier death (hazard ratio 1.95). 2 Patients with psychotic symptoms are also more likely to be admitted to a nursing home. An unresolved question is whether this more rapid progression is simply the result of greater disease activity or whether it is caused by exposure to treatments for the symptoms, resulting in a range of severe adverse events that negatively impact the patient's condition. The treatments evaluated for psychotic symptoms in AD have shown only moderate effects when comparing treated and untreated patients.
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Most of the outcome studies have evaluated atypical antipsychotics that were originally developed for schizophrenia and have been used to treat agitation and psychosis in people with dementia. Among 18 randomised controlled trials of at least 12 weeks' duration, all showed little or no benefit of treatment in reducing psychotic symptoms. Effective and well tolerated treatments for psychotic symptoms in AD therefore constitute an important unmet clinical need.
Q: What outcome measures are important when assessing new therapeutic options for psychosis in AD?
The most widely used validated scale for the assessment of psychosis in AD in trials and clinical practice is the Neuropsychiatric Inventory 
Q: What novel treatment approaches are currently under investigation?
A major challenge in the treatment of psychotic episodes in AD is the investigation of treatments other than selective serotonin reuptake inhibitors, but there have been too few studies evaluating such approaches. Approximately 15 years ago, the muscarinic agent xanolemine showed some efficacy in treating delusions, but was very poorly tolerated due to severe gastrointestinal side effects and was consequently not developed further. The treatment was well tolerated with no significant safety concerns.
Based on these results, pimavanserin was approved for this indication in the US. A UK clinical trial of pimavanserin for psychotic episodes is nearing completion and the results will be available soon. While one or two other classes of drug may offer future potential for psychosis in AD, currently only the atypical antipsychotics have an evidence base indicating that they provide efficacy benefits in this indication without a substantial risk of severe side effects.
In addition, visual hallucinations in AD can be triggered by cataracts. 8 The incidence of cataract rises with age and they are often not treated quickly. It would therefore be worthwhile investigating whether prompt treatment of cataract and other visual conditions would reduce the incidence and severity of hallucinations in patients with AD. Other novel treatments include non-drug approaches such as psychological and cognitive therapies, and physical exercise, but investigation of these specifically for psychotic episodes in AD has been limited. 9 The evidence supporting these approaches in AD is not strong, although some studies suggest that cognitive stimulation may be beneficial and that exercise can slow the rate of cognitive decline; however, further studies in larger patient populations are needed. 9, 10 For some years, progress in developing effective treatments for psychosis in AD has largely stalled. Current treatments are not satisfactory but few more effective and tolerable alternatives have emerged. The development of safer and more optimal treatments needs to be given greater priority. This should include both pharmacological and non-pharmacological approaches. While this situation may appear bleak, treatments are advancing, but not with the speed or resources that they need. With ageing populations worldwide, the prevalence of AD is certain to grow in the coming decades, and associated psychotic symptoms are likely to increase the heavy burden and worsen prognoses for patients with this disease. For this reason, greater efforts are needed to increase the pace of research in developing better means of managing this common and harmful consequence of AD.
